Table 4 Effects on outcomes after 6 and 12Â months of follow-up for both treatment groups according to the intention-to-treat principle, girls only
From: One-year effects of two intensive inpatient treatments for severely obese children and adolescents
| Â | Short-stay | Long-stay | Crude | Adjusted |
|---|---|---|---|---|
Mean (SD) | Mean (SD) | Beta (95Â % CI) | Beta (95Â % CI) | |
Primary outcome measure | ||||
SDS-BMI | ||||
 Baseline | 3.3 (0.3) | 3.3 (0.3) |  |  |
 6-months | 3.0 (0.5) | 2.8 (0.5) | 0.19 (0.06; 0.31) | 0.20 (0.07; 0.33) |
 12-months | 3.0 (0.5) | 3.0 (0.6) | 0.06 (−0.16; 0.28) | 0.07 (−0.14; 0.28) |
 Overall effecta |  |  | 0.08 (−0.14; 0.30) | 0.06 (−0.17; 0.30) |
Secondary outcomes | ||||
SDS-waist circumference | ||||
 Baseline | 3.0 (0.3) | 3.0 (0.3) |  |  |
 6-months | 2.6 (0.4) | 2.5 (0.5) | 0.10 (−0.05; 0.25) | 0.10 (−0.06; 0.26) |
 12-months | 2.6 (0.6) | 2.6 (0.6) | −0.03 (−0.27; 0.22) | −0.07 (−0.28; 0.15) |
 Overall effecta |  |  | 0.05 (−0.15; 0.26) | −0.00 (−0.22; 0.22) |
Systolic blood pressure (mmHg) | ||||
 Baseline | 122.0 (11.2) | 118.7 (12.6) |  |  |
 6-months | 115.2 (11.5) | 114.3 (14.1) | −2.25 (−6.63; 2.13) | −2.39 (−6.75; 1.96) |
 12-months | 117.3 (10.9) | 117.9 (15.9) | −3.71(−9.22; 1.81) | −4.17 (−10.08; 1.74) |
 Overall effecta |  |  | 1.32 (−4.84; 7.49) | −0.27 (−6.22; 5.68) |
Diastolic blood pressure (mmHg) | ||||
 Baseline | 74.8(9.5) | 76.3 (13.6) |  |  |
 6-months | 70.2 (7.5) | 68.4 (12.2) | 2.31 (−1.52; 6.13) | 1.94 (−2.19; 6.07) |
 12-months | 68.3 (8.3) | 67.5 (12.5) | 1.28 (−3.24; 5.80) | 0.68 (−4.19; 5.55) |
 Overall effecta |  |  | −0.32 (−5.57, 4.92) | −0.56 (−5.86, 4.75) |
Fasting insulin (μU/L) | ||||
 Baseline | 13.2 (10.0) | 13.6 (6.4) |  |  |
 6-months | 11.7 (7.8) | 13.6 (10.9) | −2.18 (−6.87; 2.51) | −3.21 (−8.78; 2.37) |
 12-months | 11.9 (10.2) | 13.9 (7.2) | −1.68 (−5.66; 2.30) | −3.21 (−7.96; 1.55) |
 Overall effecta |  |  | −1.42 (−5.32; 2.48) | −3.68 (−6.88; 0.48) |
2 h-insulin (μU/L) | ||||
 Baseline | 68.7 (50.5) | 65.5 (38.0) |  |  |
 6-months | 62.3 (52.9) | 60.6 (43.5) | −6.39 (−28.67; 15.90) | −7.93 (−31.08; 15.22) |
 12-months | 68.9 (50.4) | 67.0 (65.4) | −2.70 (−37.22; 31.81) | −4.80 (−38.42; 28.82) |
 Overall effecta |  |  | 0.16 (−32.31 21.64) | −10.37 (−27.09; 6.36) |
Fasting glucose (mmol/L) | ||||
 Baseline | 4.8 (0.4) | 4.7 (0.2) |  |  |
 6-months | 4.8 (0.4) | 4.8 (0.4) | −0.05 (−0.23; 0.12) | −0.09 (−0.28; 0.10) |
 12-months | 4.8 (0.4) | 4.8 (0.3) | 0.01 (−0.15; 0.17) | 0.06 (−0.09; 0.22) |
 Overall effecta |  |  | 0.01 (−0.15; 0.16) | 0.02 (−0.13; 0.17) |
2Â h-glucose (mmol/L) | ||||
 Baseline | 5.9 (1.3) | 5.6 (1.2) |  |  |
 6-months | 5.2 (1.0) | 5.3 (1.1) | −0.26 (−0.77; 0.25) | −0.23 (−0.80; 0.34) |
 12-months | 5.8 (1.2) | 4.9 (1.4) | 0.73 (−0.01; 1.48) | 0.71 (−0.11; 1.54) |
 Overall effecta |  |  | 0.34 (−0.18; 0.87) | 0.21 (−0.24; 0.66) |
HDL-cholesterol (mmol/L) | ||||
 Baseline | 1.1 (0.2) | 1.0 (0.2) |  |  |
 6-months | 1.2 (0.2) | 1.1 (0.2) | 0.11 (0.03; 0.19) | 0.11 (0.03; 0.19) |
 12-months | 1.2 (0.2) | 1.2 (0.3) | −0.07 (−0.18; 0.05) | −0.03 (−0.14; 0.09) |
 Overall effecta |  |  | 0.08 (−0.02; 0.18) | 0.10 (−0.01; 0.21) |
Triglycerides (mmol/L) | ||||
 Baseline | 1.0 (0.6) | 0.9 (0.3) |  |  |
 6-months | 1.1 (1.1) | 0.9 (0.3) | −0.01 (−0.24, 0.21) | −0.05 (−0.25, 0.15) |
 12-months | 1.1 (1.0) | 0.9 (0.3) | 0.08 (−0.16, 0.32) | 0.03 (−0.19, 0.25) |
 Overall effecta |  |  | 0.22 (−0.09, 0.54) | 0.11 (−0.13, 0.36) |
HOMA-IR | ||||
 Baseline | 2.8 (2.3) | 2.9 (1.4) |  |  |
 6-months | 2.5 (1.7) | 2.9 (2.4) | −0.49 (−1.53; 0.55) | −0.73 (−1.96; 0.51) |
 12-months | 2.5 (2.2) | 3.0 (1.6) | −0.40 (−1.31, 0.51) | −0.63 (−1.72, 0.46) |
 Overall effecta |  |  | −0.29 (−1.13; 0.55) | −0.75 (−1.46; 0.04) |